PDF(Pubmed)
Abstract：
UNASSIGNED: Aneurysmal bone cysts (ABCs) are aggressive and benign tumors that primarily affect children and adolescents. The standard course of treatment for ABCs involves surgical excision or curettage with a bone transplant or cement to repair the deficiency. Denosumab, a monoclonal antibody that inhibits receptor activator of nuclear kappa B ligand, is used to treat osteoporosis, skeletal metastasis, and giant cell tumors of the bones.
UNASSIGNED: This case study details the therapeutic treatment of a female patient, age 22, who had a recurring aggressive ABC of the distal tibia. The patient was initially treated using curettage and lesion filling. However, recurrence of the osteolysis was observed 9 months later that led to subsequent interventions involving absolute alcohol sclerotherapy in multiple sessions. However, these interventions failed to achieve ossification. Following unsuccessful surgical and sclerotherapy treatments, the patient was administered denosumab, which led to a positive response. Regular radiographic and clinical follow-up demonstrated significant improvements in ossification and pain reduction. During the course of the 12-month treatment, the frequency of visits was gradually reduced. Further, follow-up and monitoring revealed the effectiveness of the local control and long-term treatment.
UNASSIGNED: This case report highlights the ability of denosumab to manage recurrent aggressive ABCs after surgical or sclerotherapy failure.
UNASSIGNED: This case study details the therapeutic treatment of a female patient, age 22, who had a recurring aggressive ABC of the distal tibia. The patient was initially treated using curettage and lesion filling. However, recurrence of the osteolysis was observed 9 months later that led to subsequent interventions involving absolute alcohol sclerotherapy in multiple sessions. However, these interventions failed to achieve ossification. Following unsuccessful surgical and sclerotherapy treatments, the patient was administered denosumab, which led to a positive response. Regular radiographic and clinical follow-up demonstrated significant improvements in ossification and pain reduction. During the course of the 12-month treatment, the frequency of visits was gradually reduced. Further, follow-up and monitoring revealed the effectiveness of the local control and long-term treatment.
UNASSIGNED: This case report highlights the ability of denosumab to manage recurrent aggressive ABCs after surgical or sclerotherapy failure.
摘要：
■动脉瘤性骨囊肿（ABCs）是侵袭性和良性肿瘤，主要影响儿童和青少年。ABCs的标准治疗过程包括手术切除或刮除，并进行骨移植或水泥以修复缺陷。Denosumab,抑制核κB配体受体激活剂的单克隆抗体，用于治疗骨质疏松症，骨转移,和骨骼巨细胞瘤。
■本案例研究详细介绍了一名女性患者的治疗方法，年龄22岁，患有胫骨远端复发性侵袭性ABC。患者最初使用刮宫和病变填充进行治疗。然而,9个月后观察到骨质溶解的复发,这导致随后的干预措施包括在多个疗程中进行无水酒精硬化治疗.然而,这些干预措施未能实现骨化。在手术和硬化治疗不成功之后，病人服用了denosumab，这导致了积极的回应。定期的影像学和临床随访显示骨化和疼痛减轻的显着改善。在12个月的治疗过程中，访问频率逐渐减少。Further,随访和监测显示了局部控制和长期治疗的有效性。
■本病例报告强调了denosumab在手术或硬化治疗失败后治疗复发性侵袭性ABCs的能力。
■本案例研究详细介绍了一名女性患者的治疗方法，年龄22岁，患有胫骨远端复发性侵袭性ABC。患者最初使用刮宫和病变填充进行治疗。然而,9个月后观察到骨质溶解的复发,这导致随后的干预措施包括在多个疗程中进行无水酒精硬化治疗.然而,这些干预措施未能实现骨化。在手术和硬化治疗不成功之后，病人服用了denosumab，这导致了积极的回应。定期的影像学和临床随访显示骨化和疼痛减轻的显着改善。在12个月的治疗过程中，访问频率逐渐减少。Further,随访和监测显示了局部控制和长期治疗的有效性。
■本病例报告强调了denosumab在手术或硬化治疗失败后治疗复发性侵袭性ABCs的能力。
